Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCOFID-P-B in BCG-Unresponsive Bladder CIS
NCT04798703Phase 1Completed
- Sponsor
- Fidia Farmaceutici
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of Oncofid-P-B in bladder carcinoma in situ (CIS), sponsored by Fidia Farmaceutici. Primary endpoints: Adverse Events at 15 months and Laboratory Test Values at 15 months. Started May 2017; status: completed.
02
Drugs
Oncofid-P-B
03
Conditions
bladder carcinoma in situ (CIS)
Beyond the preview
Go deeper on NCT04798703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798703.